NewsRoom Articles - Page 21 of 229

WednesdayAug 06, 2025 11:30 am

HeartBeam Inc. (NASDAQ: BEAT) FDA-Cleared System Provides Momentum as Company Moves to Innovate Cardiac Care

The FDA-cleared HeartBeam system enables patients and physicians to access significant arrhythmia data outside traditional clinical settings. The HeartBeam system, credit card–sized and fully portable, represents a breakthrough in ambulatory cardiac care. Beyond ambulatory arrhythmia assessment, the platform is poised for future advancements, including synthesized 12-lead ECG generation. Foundational clearance from the U.S. Food and Drug Administration (“FDA”) for its patented HeartBeam system has proved pivotal for HeartBeam (NASDAQ: BEAT), a cardiac technology company focused on transforming the cardiac-care space (https://ibn.fm/0TAG4). The first cable-free, high-fidelity ECG device that captures the heart’s electrical activity from three distinct directions, the HeartBeam system…

WednesdayAug 06, 2025 10:50 am

Nutriband Inc. (NASDAQ: NTRB) Navigates Drug-Delivery Challenges with Innovation in Abuse-Deterrent Tech

Drug delivery plays a critical role in modern healthcare, but when it comes to potent opioids such as fentanyl, the stakes are particularly high Nutriband is developing Aversa(TM), a proprietary abuse-deterrent transdermal technology designed to prevent diversion, misuse, abuse and accidental exposure Nutriband’s Aversa(TM) fentanyl patch is estimated to have a market potential of $80 million to $200 million annually within five years of launch Developing safe, effective and abuse-deterrent delivery systems for controlled substances such as fentanyl is a formidable challenge, and Nutriband (NASDAQ: NTRB) is positioning itself at the forefront of that effort. The company is pioneering transdermal technologies to…

TuesdayAug 05, 2025 11:15 am

HeartBeam Inc.’s (NASDAQ: BEAT) Two New U.S. Patents Power Next Generation of Cardiac Diagnostics

Two newly issued patents mark a strategic advancement in HeartBeam’s proprietary technology. The first patent protects the company’s credit card–sized, cable-free 3D ECG device designed to capture high-fidelity electrical signals from three noncoplanar directions. The second patent covers the company’s rhythm analysis algorithm by continuously analyzing signal input. HeartBeam (NASDAQ: BEAT), a cardiac technology company, has secured two new U.S. patents that significantly enhance its intellectual property portfolio and strengthen its position in cardiac monitoring technology (https://ibn.fm/6xni4). The company, focused on delivering powerful, personalized insights into heart health through its innovative 3D ECG platform, now holds more than 20 U.S.…

TuesdayAug 05, 2025 10:00 am

Study Finds That Inflammation Markers in Diabetics Influence Depression Treatment Outcomes

On average, diabetics tend to suffer from depression at higher rates than is seen in the general population. A new study conducted by a team at the German Diabetes Center and other institutions in Germany has found that the markers of chronic inflammation influence how successful the treatments provided for depression will be for patients living with diabetes. The study found that there are significant differences between the chronic inflammation biomarkers in people with Type 1 diabetes and those in people with Type 2 diabetes. The findings of this research could help to personalize the ways in which depression is…

TuesdayAug 05, 2025 9:00 am

Nutriband Inc. (NASDAQ: NTRB) Aligns Shareholder Value with FDA Milestone

FDA approval is a powerful inflection point in the lifecycle of any biopharmaceutical company Nutriband’s recent 25% preferred stock dividend uniquely ties shareholder reward to regulatory achievement CEO notes that “core goal is to continue to create value for our shareholders particularly as we near closer to the commercialization of AVERSA(TM) Fentanyl” Obtaining approval from the U.S. Food and Drug Administration (“FDA”) is a monumental achievement for any biopharmaceutical company, serving as a critical validation of a drug's safety and efficacy. This rigorous process is a cornerstone of public health, ensuring that only treatments proven to be beneficial and with acceptable…

FridayAug 01, 2025 10:00 am

Study Identifies Genetic Marker Helpful in Guiding Brain Tumor Treatment

Researchers at the University of Kentucky have identified a key genetic biomarker that treatment teams could rely on to predict which patients having glioblastoma stand higher chances of benefiting from bevacizumab, a cancer drug. The study, whose findings were published in the journal JCO Precision Oncology, found that patients who had a genetic alteration referred to as CDK4 and were treated using bevacizumab tended to have longer survival times when compared to patients that underwent the same treatment but didn’t have this genetic change. This finding suggests that conducting tests to identify this particular genetic change could help medical teams…

ThursdayJul 31, 2025 10:00 am

New AI-Based Speech Tool Detects Possibility of Parkinson’s Disease

Computer scientists have designed an AI-based speech screening tool that could help people ascertain whether they could be exhibiting signs of Parkinson’s. The research explaining this speech tool appeared in the npj Parkinson’s Disease journal. According to the researchers, all that a person has to do is to say aloud two short sentences that contain every single letter of the alphabet, 26 letters in total. Such sentences are referred to as pangrams, and the web-based tool utilizes two such sentences. In just a matter of seconds, the AI tool is able to analyze the way in which someone has spoken…

TuesdayJul 29, 2025 1:45 pm

Why Izotropic Corp. (CSE: IZO) (OTCQB: IZOZF) Is ‘One to Watch’

Izotropic is the only commercial entity with exclusive global rights to the Breast CT technology developed at UC Davis. The company has secured regulatory alignment with the FDA and is preparing for a pivotal U.S. clinical trial. IzoView offers a proprietary, patient-centric alternative to mammography for dense breast tissue imaging. A comprehensive business and financial plan supports execution across clinical, regulatory, and commercial milestones. Awareness campaigns, including breastct.com and a company podcast, are primed to drive engagement and investor visibility. Izotropic (CSE: IZO) (OTCQB: IZOZF) is a medical device company advancing dedicated imaging solutions to improve the screening, diagnosis, and treatment of…

TuesdayJul 29, 2025 10:00 am

Study Discovers That Autoantibodies in Patients Could Boost Cancer Immunotherapy

For years, oncologists have been baffled by why checkpoint inhibitors work for some cancer patients and not others. This challenge has made it difficult for these immunotherapies to be widely used since it isn’t easy to predict who will benefit and yet the treatments are currently very expensive. Now a new study whose findings appeared in the journal Nature has found that autoantibodies, the proteins known to drive autoimmune diseases like rheumatoid arthritis and lupus, could be the missing link that helps checkpoint inhibitors to be more effective against different kinds of cancer and other diseases. Doctor Aaron Ring, the…

MondayJul 28, 2025 9:00 am

Clene Inc. (NASDAQ: CLNN) Offers Investors a Compelling Entry into the Growing ALS Market with Key FDA Milestones for Lead Drug Candidate

Clene is progressing toward a potential FDA accelerated approval for its ALS (Amyotrophic Lateral Sclerosis) drug CNM-Au8® in 2026, a market that is expected to reach $1.3 billion by 2034 with significant unmet need. Clene’s technology targets mitochondrial dysfunction, a novel approach to neurodegenerative diseases, and key FDA meetings in the coming months of 2025 could be major valuation catalysts for investors. Biomarker and survival data from over 150 patients will be critical to the company’s regulatory case and expects important NfL data in the fourth quarter of 2025. Clene is preparing to initiate a confirmatory Phase 3 ALS trial…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

HeartBeam Inc. (NASDAQ: BEAT) FDA-Cleared System Provides Momentum as Company Moves to Innovate Cardiac Care

Nutriband Inc. (NASDAQ: NTRB) Navigates Drug-Delivery Challenges with Innovation in Abuse-Deterrent Tech

HeartBeam Inc.’s (NASDAQ: BEAT) Two New U.S. Patents Power Next Generation of Cardiac Diagnostics

Study Finds That Inflammation Markers in Diabetics Influence Depression Treatment Outcomes

Nutriband Inc. (NASDAQ: NTRB) Aligns Shareholder Value with FDA Milestone

Study Identifies Genetic Marker Helpful in Guiding Brain Tumor Treatment

New AI-Based Speech Tool Detects Possibility of Parkinson’s Disease

Why Izotropic Corp. (CSE: IZO) (OTCQB: IZOZF) Is ‘One to Watch’

Study Discovers That Autoantibodies in Patients Could Boost Cancer Immunotherapy

Clene Inc. (NASDAQ: CLNN) Offers Investors a Compelling Entry into the Growing ALS Market with Key FDA Milestones for Lead Drug Candidate

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search